In case of ALS neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) is elevated in presymptomatically and continue to rise in the early stages of the disease and recently regarded as promising prognostic and diagnostic biomarkers (Zucchi et al., 2020), nevertheless, no validated studies have shown the consistency of increase in p-tau181 and p-tau217 during the clinical progression of ALS starting from presymptomatic phase to symptomatic phase. Here, NEFH is linked to amyotrophic lateral sclerosis.